RBC Analyst Updates Top 40 Domestic Stock Picks List, Adds Iamgold and Aecon, Removes Cenovus and OceanaGold.
ByAinvest
Monday, Jul 7, 2025 8:08 am ET1min read
CVE--
Goldman Sachs' Briefings report highlighted the current rally's unloved nature, citing moderate hedge fund positioning and strong passive flows from corporate buybacks and retail 401(k) buying. Scotiabank's bullishness on Canadian equities relative to the U.S. has almost disappeared [2].
Eli Lilly and Company (NYSE:LLY) remains one of the 13 best blue-chip stocks to buy, according to analysts. RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market. The research firm is optimistic that the trial will deliver positive results, given prior evidence that beta-amyloid therapies have been effective in earlier stages of the disease. The firm expects the company to generate $4 billion in additional US sales if the treatment is applied to just 2.5% of the estimated 15 million eligible patients. Eli Lilly has already secured marketing authorization for Kisunla from the Australian Therapeutic Goods Administration [3].
Shell Canada Energy announced the shipment of the first liquefied natural gas (LNG) cargo from its LNG Canada facility in Kitimat, British Columbia. This facility, with Shell holding a 40% stake, is expected to play a significant role in meeting growing global energy demand, particularly in Asian markets [4]. According to Shell's LNG Outlook 2025 report, global demand for LNG could increase by around 60% by 2040, driven by economic growth in Asian countries.
Constellation Brands (NYSE:STZ) saw its first-quarter earnings fall short of expectations, but Goldman Sachs reiterated its Buy rating and $225.00 price target. Despite missing earnings estimates, the company reaffirmed its comparable fiscal year 2026 guidance and highlighted potential upside in topline growth. The stock is currently undervalued, trading at a 15% discount to alcohol industry peers on a forward P/E basis [5].
References:
[1] https://finance.yahoo.com/news/eli-lilly-lly-staring-tremendous-131926774.html
[2] https://energynews.pro/en/shell-ships-first-lng-cargo-from-its-lng-canada-facility/
[3] https://www.investing.com/news/analyst-ratings/constellation-brands-stock-holds-buy-rating-at-goldman-sachs-despite-earnings-miss-93CH-4120594
GS--
IAG--
LLY--
SHEL--
RBC Capital Markets analyst Bish Koziol updated his top 40 domestic stock picks list, adding Iamgold Corp. and Aecon Group Inc. and removing Cenovus Energy Inc. and OceanaGold Corp. His Canada Overall Top 40 Portfolio gained 5.3% in June, outperforming the S&P/TSX Composite. Goldman Sachs' Briefings report highlighted the unloved nature of the current rally, citing moderate hedge fund positioning and strong passive flows from corporate buybacks and retail 401(k) buying. Scotiabank's bullishness on Canadian equities relative to the U.S. has almost disappeared.
RBC Capital Markets analyst Bish Koziol recently updated his top 40 domestic stock picks list, adding Iamgold Corp. and Aecon Group Inc. and removing Cenovus Energy Inc. and OceanaGold Corp. [1] The Canada Overall Top 40 Portfolio gained 5.3% in June, outperforming the S&P/TSX Composite.Goldman Sachs' Briefings report highlighted the current rally's unloved nature, citing moderate hedge fund positioning and strong passive flows from corporate buybacks and retail 401(k) buying. Scotiabank's bullishness on Canadian equities relative to the U.S. has almost disappeared [2].
Eli Lilly and Company (NYSE:LLY) remains one of the 13 best blue-chip stocks to buy, according to analysts. RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market. The research firm is optimistic that the trial will deliver positive results, given prior evidence that beta-amyloid therapies have been effective in earlier stages of the disease. The firm expects the company to generate $4 billion in additional US sales if the treatment is applied to just 2.5% of the estimated 15 million eligible patients. Eli Lilly has already secured marketing authorization for Kisunla from the Australian Therapeutic Goods Administration [3].
Shell Canada Energy announced the shipment of the first liquefied natural gas (LNG) cargo from its LNG Canada facility in Kitimat, British Columbia. This facility, with Shell holding a 40% stake, is expected to play a significant role in meeting growing global energy demand, particularly in Asian markets [4]. According to Shell's LNG Outlook 2025 report, global demand for LNG could increase by around 60% by 2040, driven by economic growth in Asian countries.
Constellation Brands (NYSE:STZ) saw its first-quarter earnings fall short of expectations, but Goldman Sachs reiterated its Buy rating and $225.00 price target. Despite missing earnings estimates, the company reaffirmed its comparable fiscal year 2026 guidance and highlighted potential upside in topline growth. The stock is currently undervalued, trading at a 15% discount to alcohol industry peers on a forward P/E basis [5].
References:
[1] https://finance.yahoo.com/news/eli-lilly-lly-staring-tremendous-131926774.html
[2] https://energynews.pro/en/shell-ships-first-lng-cargo-from-its-lng-canada-facility/
[3] https://www.investing.com/news/analyst-ratings/constellation-brands-stock-holds-buy-rating-at-goldman-sachs-despite-earnings-miss-93CH-4120594
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet